Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679854 | 0.91 | ALOX5AP (0.48) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL30193098 | 0.91 | ALOX5AP (0.48) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL19107653 | 0.90 | ALOX5AP (0.48) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL20438981 | 0.87 | GPR119 (0.51) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL31342284 | 0.85 | STS (0.51) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL26128483 | 0.85 | KDM4E (0.48) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL18589203 | 0.83 | GPR119 (0.46) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL24266104 | 0.82 | ALOX5AP (0.46) | ALOX5APFEN1KDM4EMAPTTHRB | |
| SCHEMBL1808004 | 0.81 | GPR119 (0.51) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL29535803 | 0.81 | GPR119 (0.56) | ALOX5APFEN1KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | ALOX5AP 4151/4885FEN1 1149/4885KDM4E 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.